Fosun Antigen IPO: Industry Rankings 'Inflated,' Listing Backstopped by Parent Group; Commercial Prospects of Pipeline Remain Unpromising

Recently, Fosun Pharma's vaccine platform, Fosun Antegen, formally submitted its listing application to the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) and Fosun International Capital acting as joint sponsors. As another subsidiary of the Fosun Group advancing toward a spin-off listing, Antegen is seeking entry into the Hong Kong market with four commercialized products and over ten candidates in its pipeline. According to prospectus data, Fosun Antegen reported revenue of RMB 526 million in 2025, a substantial year-over-year increase of 546.5%, while its net loss narrowed to RMB 71.267 million. However, a deeper analysis of its financial structure, product portfolio, R&D pipeline, and governance framework reveals multiple underlying risks that cannot be overlooked. Rabies vaccines alone accounted for 70% of its revenue, raising industry concerns.

Sina FinanceJul 3 16:48

IPO News | Fosun Antigen Files Application with HKEX, Focused on Vaccine Business, Still Not Profitable During Reporting Period

According to a disclosure by the Hong Kong Stock Exchange on June 26, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd. has submitted an application for listing on the Main Board of the Hong Kong Stock Exchange.

Zhitong FinanceJun 26 21:20